Psyence Biomedical (PBM) News Today → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free PBM Stock Alerts $0.98 +0.12 (+14.10%) (As of 09:45 AM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePsyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)finance.yahoo.com - April 17 at 12:49 PMPsyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)globenewswire.com - April 17 at 8:00 AMPsyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trialglobenewswire.com - April 16 at 11:01 AMPsyence Biomed Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin Trialtmcnet.com - April 8 at 12:13 PMPsyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trialglobenewswire.com - April 8 at 8:00 AMPsyence Group Inc.: Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Businessfinanznachrichten.de - March 28 at 6:23 PMPsyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Businessglobenewswire.com - March 26 at 11:06 AMPsyence Biomedical Ltd PBMmorningstar.com - March 24 at 7:23 PMPBM Psyence Biomedical Ltd.seekingalpha.com - March 22 at 8:02 PMPsyence Biomedical Ltd (PBM)uk.investing.com - March 21 at 4:24 PMPsyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybinstockhouse.com - March 18 at 7:19 PMPsyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybinglobenewswire.com - March 18 at 4:05 PMPsyence Biomedical faces Nasdaq delisting over market valueuk.investing.com - March 17 at 3:36 PMPsyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Sharesglobenewswire.com - March 15 at 4:30 PMPsyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Studyglobenewswire.com - March 12 at 11:15 AMPsyence Biomedical Ltd. Issues Shareholder Letter Recapping Recent Progress and Outlining Key Future Milestonesglobenewswire.com - March 12 at 7:00 AMPsyence Biomedical Will Undertake Psilocybin Clinical Trials For Palliative Care In Australiabenzinga.com - March 11 at 7:54 PMWhy Is Psyence Biomedical (PBM) Stock Up 90% Today?investorplace.com - March 8 at 6:17 PMmarketbeat.com - March 8 at 9:40 AMmarketbeat.com - January 26 at 10:29 AMmarketbeat.com - January 26 at 9:49 AM Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Email Address My top 100 stocks… (Ad)We recently ran an internal audit of every trade recommendation I’ve published across all my services… And let me tell ya, we found some incredible insights… For starters, we found about 100 stocks I trade really, really well. Get some cool freebies right here. PBM Media Mentions By Week PBM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PBM News Sentiment▼1.000.34▲Average Medical News Sentiment PBM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PBM Articles This Week▼11▲PBM Articles Average Week Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CERo Therapeutics News Vaccinex News Syra Health News Hoth Therapeutics News Kazia Therapeutics News Ayala Pharmaceuticals News Kineta News XWELL News Avenue Therapeutics News Protagenic Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PBM) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsBiden out June 13; Kamala won’t replace him?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
